Eagle Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2016 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Eagle Pharmaceuticals (EGRX) Tops Q4 EPS by 66c, Sales Miss
March 1, 2017 6:52 AM ESTEagle Pharmaceuticals (NASDAQ: EGRX) reported Q4 EPS of $3.52, $0.66 better than the analyst estimate of $2.86. Revenue for the quarter came in at $81.1 million versus the consensus estimate of $86.13 million.
Total revenue for the fourth quarter of 2016 grew 346% to $81.1 million;Product sales increased to $9.1 million compared to $2.9 million in Q4... More